2025WCLC会议明日来袭！恒生创新药ETF（159316）涨超4%，近5日“吸金”2.9亿！

Group 1 - The Hong Kong innovative drug sector experienced significant gains, with companies such as Sangfor Biopharma, Eucure Biopharma, and CanSino Biologics rising by 16%, 13%, and 12% respectively, leading to a 4.54% increase in the Hang Seng Innovative Drug ETF (159316) [1] - The World Lung Cancer Conference (WCLC) is scheduled from September 6 to 9, where Chinese pharmaceutical companies such as CanSino Biologics, BeiGene, Junshi Biosciences, and Bairui Tianheng will present their latest research advancements [1] - The trend of Chinese innovative drugs going global is becoming normalized, with the amount of License out (patent authorization abroad) reaching nearly $80 billion from January to July, a year-on-year increase of over 160% [1] Group 2 - Recent U.S. employment data supports a potential interest rate cut in September, which could lead to a favorable investment environment and new breakthroughs in the global innovative drug industry, benefiting Chinese innovative drugs [1] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which has been updated to exclude CXO, making it a 100% "pure" innovative drug index that accurately reflects the overall performance of Chinese innovative pharmaceutical companies [1] - The ETF has attracted significant capital inflow, with a total of 290 million yuan in the past five days and over 1.6 billion yuan in the last 60 days [1]